Lessons learned about gene therapy for neuromuscular disorders

In a panel discussion held at WMS 2020, experts in the field of gene therapy for neuromuscular disorders (NMDs) discussed dosing and safety issues for novel gene-based therapies.

The key points of the discussion included:

    Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

    No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.